Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Other)

Overall Status

Recruiting

CT.gov ID

NCT01203722

Collaborator

National Cancer Institute (NCI) (NIH)

100

Enrollment

Location

Arms

159

Anticipated Duration (Months)

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served. Towards this goal, the current study extends our platform of nonmyeloablative, partially HLA-mismatched bone marrow transplant (BMT) and Peripheral Blood Stem Cell Transplant (PBSCT) to the use of such donors, investigating up to several postgrafting immunosuppression regimens that incorporate high-dose Cy. Of central interest is the incorporation of sirolimus into this postgrafting immunosuppression regimen.

The primary goal for phase 1 is to identify a transplant regimen associated with acceptable rates of severe acute GVHD and NRM by Day 100 and for phase 2 estimate the 6-month probability of survival without having had acute grade III- IV GVHD or graft failure.

Condition or Disease	Intervention/Treatment	Phase
Hematologic Malignancies	Drug: Fludarabine Drug: Cytoxan Radiation: Total Body Irradiation Procedure: Allogeneic Blood or Marrow Transplant Procedure: Peripheral Blood Stem Cell Transplant Drug: Mycophenolate Mofetil Drug: Sirolimus Drug: Tacrolimus	Phase 1/Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

100 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Reduced Intensity, Partially HLA Mismatched Allogeneic BMT for Hematologic Malignancies Using Donors Other Than First-degree Relatives

Actual Study Start Date :

Sep 1, 2010

Anticipated Primary Completion Date :

Sep 1, 2023

Anticipated Study Completion Date :

Dec 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: REGIMEN B Pre-BMT : Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV Day -1: 400 cGy total body irradiation (TBI) administered in a single fraction Day 0: Allogeneic blood or marrow transplantation (BMT) Post-Transplantation Immunosuppression Consisting of: Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV Day 5: Sirolimus loading dose 6 mg PO once Day 5 thru Day 35: Mycophenolate Mofetil (MMF) 15 mg/kg PO TID (maximum daily dose 3 g/day) Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL	Drug: Fludarabine Fludarabine 30 mg/m2/day Drug: Cytoxan Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day Other Names: High-dose Cytoxan Radiation: Total Body Irradiation 400 cGy TBI administered in a single fraction Other Names: TBI Procedure: Allogeneic Blood or Marrow Transplant Other Names: BMT Drug: Mycophenolate Mofetil 15mg/kg by mouth three times daily Other Names: MMF Drug: Sirolimus Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily
Active Comparator: REGIMEN C Pre-BMT: Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV Day -1: 400 cGy TBI administered in a single fraction Day 0: BMT Post-Transplantation Immunosuppression Consisting of: Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day) Day 5 thru Day 180: Tacrolimus 1 mg administered IV QD	Drug: Fludarabine Fludarabine 30 mg/m2/day Drug: Cytoxan Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day Other Names: High-dose Cytoxan Radiation: Total Body Irradiation 400 cGy TBI administered in a single fraction Other Names: TBI Procedure: Allogeneic Blood or Marrow Transplant Other Names: BMT Drug: Mycophenolate Mofetil 15mg/kg by mouth three times daily Other Names: MMF Drug: Tacrolimus Tacrolimus 1mg intravenously, daily
Active Comparator: REGIMEN B2 Pre-PBSCT: Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV Day -1: 400 cGy TBI administered in a single fraction Day 0: Peripheral Blood Stem Cell Transplant (PBSCT) Post-Transplantation Immunosuppression Consisting of: Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV Day 5: Sirolimus loading dose 6 mg PO once Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day) Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL	Drug: Fludarabine Fludarabine 30 mg/m2/day Drug: Cytoxan Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day Other Names: High-dose Cytoxan Radiation: Total Body Irradiation 400 cGy TBI administered in a single fraction Other Names: TBI Procedure: Peripheral Blood Stem Cell Transplant Other Names: PBSCT Drug: Mycophenolate Mofetil 15mg/kg by mouth three times daily Other Names: MMF Drug: Sirolimus Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily
Active Comparator: REGIMEN B3: HIV patients with CCRd32 homozygous donors Pre-PBSCT: Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV Day -1: 400 cGy TBI administered in a single fraction Day 0: Peripheral Blood Stem Cell Transplant (PBSCT) Post-Transplantation Immunosuppression Consisting of: Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV Day 5: Sirolimus loading dose 6 mg PO once Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day) Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL	Drug: Fludarabine Fludarabine 30 mg/m2/day Drug: Cytoxan Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day Other Names: High-dose Cytoxan Radiation: Total Body Irradiation 400 cGy TBI administered in a single fraction Other Names: TBI Procedure: Peripheral Blood Stem Cell Transplant Other Names: PBSCT Drug: Mycophenolate Mofetil 15mg/kg by mouth three times daily Other Names: MMF Drug: Sirolimus Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily

Outcome Measures

Primary Outcome Measures

Transplant regimen as determined by rates of severe acute graft-versus-host-disease (GVHD) [Study Day 100]
Two immunosuppressive regimens with Fludarabine-Cytoxan-TBI conditioning will be studied in reduced-intensity, partially HLA mismatched allogeneic BMT from unrelated or non-first-degree related donors. Transplant regimen will be determined by acceptable rates of severe acute GVHD (< 25%).
Transplant regimen as determined by rates of transplant-related nonrelapse mortality (NRM) [Study Day 100]
Two immunosuppressive regimens with Fludarabine-Cytoxan-TBI conditioning will be studied in reduced-intensity, partially HLA mismatched allogeneic BMT from unrelated or non-first-degree related donors. Transplant regimen will be determined by acceptable rates transplant-related NRM (< 20%).
6-month probability of survival as assessed by absence of grade III-IV GVHD or evidence of graft failure. [6 months]
Two immunosuppressive regimens with Fludarabine-Cytoxan-TBI conditioning will be studied in reduced-intensity, partially HLA mismatched allogeneic BMT from unrelated or non-first-degree related donors.

Secondary Outcome Measures

Progression-free survival [7 years]
All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.
Event-free survival [7 years]
All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.
Overall survival [7 years]
All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.
Cumulative incidence of progression or relapse [7 years]
All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.
Cumulative incidence of NRM. [7 years]
All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.
Cumulative incidence of acute grade II-IV GVHD. [1 year]
All suspected cases of acute GVHD must be confirmed histologically by biopsy of an affected organ (skin, liver, or gastrointestinal tract). Date of symptom onset, date of biopsy confirmation of GVHD, maximum clinical grade, and dates and types of treatment will be recorded. Dates of symptom onset of grade II or higher GVHD and grade III-IV GVHD will be recorded.
Cumulative incidence of acute grade III-IV GVHD [1 year]
All suspected cases of acute GVHD must be confirmed histologically by biopsy of an affected organ (skin, liver, or gastrointestinal tract). Date of symptom onset, date of biopsy confirmation of GVHD, maximum clinical grade, and dates and types of treatment will be recorded. Dates of symptom onset of grade II or higher GVHD and grade III-IV GVHD will be recorded.
Cumulative incidence of chronic GVHD [1 year]
All suspected cases of acute GVHD must be confirmed histologically by biopsy of an affected organ (skin, liver, or gastrointestinal tract). Date of symptom onset, date of biopsy confirmation of GVHD, maximum clinical grade, and dates and types of treatment will be recorded. Dates of symptom onset of grade II or higher GVHD and grade III-IV GVHD will be recorded.

Eligibility Criteria

Criteria

Ages Eligible for Study:

6 Months to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Patient Inclusion Criteria:

Patient age 0.5-75 years
Absence of a suitable related or unrelated bone marrow donor who is molecularly matched at HLA-A, B, Cw, DRB1, and DQB1.
Absence of a suitable partially HLA-mismatched (haploidentical), first-degree related donor. Donors who are homozygous for the CCR5delta32 polymorphism are given preference.
Eligible diagnoses:
Relapsed or refractory acute leukemia in second or subsequent remission, with remission defined as <5% bone marrow blasts morphologically
Poor-risk acute leukemia in first remission, with remission defined as <5% bone marrow blasts morphologically:

AML with at least one of the following:
AML arising from MDS or a myeloproliferative disorder, or secondary AML
Presence of Flt3 internal tandem duplications
Poor-risk cytogenetics: Complex karyotype [> 3 abnormalities], inv(3), t(3;3), t(6;9), MLL rearrangement with the exception of t(9;11), or abnormalities of chromosome 5 or 7
Primary refractory disease
ALL (leukemia and/or lymphoma) with at least one of the following:
Adverse cytogenetics such as t(9;22), t(1;19), t(4;11), or MLL rearrangement
Clear evidence of hypodiploidy
Primary refractory disease
Biphenotypic leukemia

MDS with at least one of the following poor-risk features:

Poor-risk cytogenetics (7/7q minus or complex cytogenetics)
IPSS score of INT-2 or greater
Treatment-related MDS
MDS diagnosed before age 21 years
Progression on or lack of response to standard DNA-methyltransferase inhibitor therapy
Life-threatening cytopenias, including those generally requiring greater than weekly transfusions

Interferon- or imatinib-refractory CML in first chronic phase, or non-blast crisis CML beyond first chronic phase.
Philadelphia chromosome negative myeloproliferative disease.
Chronic myelomonocytic leukemia.
Juvenile myelomonocytic leukemia.
Low-grade non-Hodgkin lymphoma (including SLL and CLL) or plasma cell neoplasm that has:

progressed after at least two prior therapies (excluding single agent rituximab and single agent steroids), or
in the case of lymphoma undergone histologic conversion;
patients with transformed lymphomas must have stable disease or better.

Poor-risk CLL or SLL as follows:

11q deletion disease that has progressed after a combination chemotherapy regimen,
17p deletion disease,
or histologic conversion;
patients with transformed lymphomas must have stable disease or better.

Aggressive non-Hodgkin lymphoma as follows, provided there is stable disease or better to last therapy:

NK or NK-T cell lymphoma, hepatosplenic T-cell lymphoma, or subcutaneous panniculitic T-cell lymphoma, blastic/ blastoid variant of mantle cell lymphoma
Hodgkin or aggressive non Hodgkin lymphoma that has failed at least one multiagent regimen, and the patient is either ineligible for autologous BMT or autologous BMT is not recommended.
Eligible subtypes of aggressive non-Hodgkin lymphoma include:
mantle cell lymphoma
follicular grade 3 lymphoma
diffuse large B-cell lymphoma or its subtypes, excluding primary CNS lymphoma
primary mediastinal large B-cell lymphoma
large B-cell lymphoma, unspecified
anaplastic large cell lymphoma, excluding skin-only disease
Burkitt's lymphoma or atypical Burkitt's lymphoma (high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt's), in complete remission

Patients with CLL, SLL, or prolymphocytic leukemia must have < 20% bone marrow involvement by malignancy (to lower risk of graft rejection).
One of the following, in order to lower risk of graft rejection:

Cytotoxic chemotherapy, an adequate course of 5-azacitidine or decitabine, or alemtuzumab within 3 months prior to start of conditioning; or
Previous BMT within 6 months prior to start of conditioning.

NOTE: Patients who have received treatment outside of these windows may be eligible if it is deemed sufficient to reduce graft rejection risk; this will be decided on a case-by-case basis by the PI or co-PI.

Any previous BMT must have occurred at least 3 months prior to start of conditioning.
Adequate end-organ function as measured by:
Left ventricular ejection fraction greater than or equal to 35%, or shortening fraction > 25%, unless cleared by a cardiologist
Bilirubin ≤ 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST < 5 x ULN
FEV1 and FVC > 40% of predicted; or in pediatric patients, if unable to perform pulmonary function tests due to young age, oxygen saturation >92% on room air
ECOG performance status < 2 or Karnofsky or Lansky score > 60

Patient Exclusion Criteria:

Not pregnant or breast-feeding.
No uncontrolled bacterial, viral, or fungal infection.
Note: HIV-infected patients are potentially eligible. Eligibility of HIV-infected patients will be determined on a case-by-case basis.
No previous allogeneic BMT (syngeneic BMT permissible).
Active extramedullary leukemia or known active CNS involvement by malignancy. Such disease treated into remission is permitted.

Donor Inclusion Criteria:

Potential donors consist of:

Unrelated donors
Second-degree relatives
First cousins

The donor and recipient must be identical at at least 5 HLA alleles based on high resolution typing of HLA-A, -B, -Cw, -DRB1, and -DQB1, with at least one allele matched for a HLA class I gene (HLA-A, -B, or -Cw) and at least one allele matched for a class II gene (HLA-DRB1 or -DQB1).
Meets institutional selection criteria and medically fit to donate. 4 . Lack of recipient anti-donor HLA antibody. Note: In some instances, low level, non-cytotoxic HLA specific antibodies may be permissible if they are found to be at a level well below that detectable by flow cytometry. This will be decided on a case-by-case basis by the PI and one of the immunogenetics directors. Pheresis to reduce anti-HLA antibodies is permissible; however eligibility to proceed with the transplant regimen would be contingent upon the result.